Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention

Yu Miao,Zhou Yu-Jie,Y. Miao,Z. Yu-Jie

DOI: https://doi.org/10.1136/heartjnl-2011-300867.673

IF: 5.7

2011-10-01

Heart

Abstract:Contrast-induced nephropathy (CIN) is a commonly occurring complication associated with the use of contrast media in radiological studies. It impairs clinical outcome in patients undergoing angiographic procedures. The aim of this study was to investigate whether short-term high-dose atorvastatin would decreases the incidence of CIN after percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI). Statin-naive patients with STEMI undergoing PCI (n=268) randomly received high-dose atorvastatin (80 mg 12 h before intervention, n=130) or low-dose group (20 mg 12 h before intervention, n=138). All patients had long-term atorvastatin treatment thereafter (40 mg/day in high-dose group and 20 mg/day in low-dose group). Primary end point was incidence of CIN defined as postintervention increase in serum creatinine ≥0.5 mg/dl or >25% from baseline. Baseline demographic characteristics and nephropathy risk factors were similar between groups. 4.8% of patients in the high-dose group developed CIN versus 7.6% of those in the low-dose group (p<0.05). In the high-dose group, postprocedure serum creatinine was significantly lower (1.08±0.42 vs 1.14±0.38 mg/dl, p<0.05), creatinine clearance was decreased (78.9±22.2 vs 72.0±36.6 ml/min, p<0.05), multivariable analysis showed that high-dose atorvastatin pretreatment was independently associated with a decreased risk of CIN (OR 0.31, 95% CI 0.22 to 0.86, p<0.05). Short-term pretreatment with high-dose atorvastatin prevents CIN in patients with STEMI undergoing PCI.

cardiac & cardiovascular systems